Colorectal cancer screening programme: is the French faecal immunological test (FIT) threshold optimal?

Background: In France, the colorectal cancer organised screening programme uses the faecal immunological test. A positive test ⩾30 μg Hb/g of stool leads to a colonoscopy for identification of potential colorectal lesions. Cut-off values vary from 20 to 47 μg Hb/g of stool in Western countries.

Results of the national organised colorectal cancer screening program with FIT in Paris.

In France, colorectal cancer (CRC) benefits from a nationwide screening program. The faecal immunochemical test (FIT) is being used since April 2015. The test is recommended in asymptomatic patients followed by a colonoscopy if positive for identification and treatment of colorectal lesions.

Impact of a Doctor's Invitation on Participation in Colorectal Cancer Screening: A Cluster Randomized Trial.

Background: There is a need to improve participation in colorectal cancer screening. Our objective was to assess the impact of a signature from the patient's general practitioner on a letter inviting patients to participate in a colorectal cancer screening.

Method: We conducted a cluster randomized controlled trial with 57 general practitioners established in Paris for more than 5 years, randomized to intervention or usual-care arms.

Quality indicators for colonoscopy procedures: a prospective multicentre method for endoscopy units.

Background And Aims: Healthcare professionals are required to conduct quality control of endoscopy procedures, and yet there is no standardised method for assessing quality. The topic of the present study was to validate the applicability of the procedure in daily practice, giving physicians the ability to define areas for continuous quality improvement.

Methods: In ten endoscopy units in France, 200 patients per centre undergoing colonoscopy were enrolled in the study.

Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.

Background: Aspirin inhibits colorectal carcinogenesis. In a randomised double-blind placebo-controlled trial, daily soluble aspirin significantly reduced recurrence of colorectal adenomas at 1-year follow-up. In this study the results of daily intake of low-dose aspirin on polyp recurrence at 4-year follow-up are presented.

Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.

Background: Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas. Cyclooxygenase-2 (COX-2), one of its main target enzymes, is reportedly over-expressed in colorectal adenomas.

Aim: To assess COX-2 expression, in relation to adenoma recurrence and the protective effect of aspirin, in a large series of colorectal adenomas, recruited from a double-blind randomised controlled trial comparing recurrences after low-dose aspirin or placebo.

Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.

Background & Aims: Epidemiologic and experimental studies have suggested that aspirin intake reduces the risk for colorectal carcinogenesis. However, the available data are not sufficient to serve as the basis for firm recommendations.

Methods: We randomly assigned 272 patients with a history of colorectal adenomas (at least one more than 5 mm in diameter, or more than 3) to daily lysine acetylsalicylate (160 or 300 mg/day) or placebo for 4 years.

[Inter-observer agreement on histological diagnosis of colorectal polyps: the APACC study].

Introduction: Adenomas are considered as precursors of colorectal adenocarcinomas. After polypectomy, surveillance depends on the histological analysis of the excised polyps. The aim of the study was to evaluate the reproducibility of the histological diagnosis performed by pathologists from participating centers in the APACC study.